Lv4
610 积分 2022-06-22 加入
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)
8个月前
已完结
Resistance mechanisms to EGFR tyrosine‑kinase inhibitors in advanced NSCLC: molecular landscape and therapeutic strategies
10个月前
已关闭
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
10个月前
已完结
皖公网安备34019202002308
